Fredun Pharmaceuticals Limited
BSE: FREDUN
Prev Close
1106.8
Open Price
1119.95
Volume
51,104
Today Low / High
1086 / 1275
52 WK Low / High
635 / 1275
Range
1,191 - 1,317
The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 1254.05, reflecting a change of 147.25 (13.30412%). The expected target range on the BSE is 1,191 - 1,317. The stock is showing an upward trend on the BSE, making it an appealing option for investors looking for growth in their portfolio.
Fredun Pharmaceuticals Limited Graph
Fredun Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Fredun Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,254.05, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,254.05 | 1,266.59 | 1,139.93 - 1,393.25 |
| 1,279.13 | 1,023.30 - 1,534.96 | ||
| 1,291.67 | 904.17 - 1,679.17 | ||
| Bearish Scenario | 1,254.05 | 1,241.51 | 1,117.36 - 1,365.66 |
| 1,228.97 | 983.18 - 1,474.76 | ||
| 1,216.43 | 851.50 - 1,581.36 |
Overview of Fredun Pharmaceuticals Limited
ISIN
INE194R01017
Industry
Medical - Pharmaceuticals
Vol.Avg
20,289
Market Cap
5,921,197,723
Last Dividend
0.7
Official Website
IPO Date
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of FREDUN
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-09-23 | September 23, 24 | 0.7 | 0.7 | 2024-09-23 | 2024-10-30 | |
| 2023-09-22 | September 22, 23 | 0.7 | 0.7 | 2023-09-22 | 2023-10-29 | |
| 2022-09-14 | September 14, 22 | 0.7 | 0.7 | 2022-09-15 | 2022-10-30 | |
| 2021-09-16 | September 16, 21 | 0.7 | 0.7 | 2021-09-18 | 2021-10-27 | |
| 2020-09-18 | September 18, 20 | 0.66 | 0.66 | 2020-09-21 | 2020-10-28 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 451.71 Cr | 347.59 Cr | 104.12 Cr | 0.2305 | 0.00 Cr | 0.19 Cr | 47.42 Cr | 19.74 Cr | 44.83 | 54.91 Cr | 0.0437 |
| 2024-03-31 | 346.58 Cr | 275.68 Cr | 70.89 Cr | 0.2045 | 1.56 Cr | 5.30 Cr | 36.43 Cr | 15.62 Cr | 33.66 | 37.77 Cr | 0.0451 |
| 2023-03-31 | 274.34 Cr | 218.27 Cr | 56.07 Cr | 0.2044 | 0.01 Cr | 3.27 Cr | 24.99 Cr | 10.81 Cr | 24.13 | 27.93 Cr | 0.0394 |
| 2022-03-31 | 221.74 Cr | 184.26 Cr | 37.48 Cr | 0.1690 | 0.01 Cr | 2.12 Cr | 11.73 Cr | 6.34 Cr | 15.26 | 15.43 Cr | 0.0286 |
| 2021-03-31 | 131.48 Cr | 107.02 Cr | 24.46 Cr | 0.1861 | 0.03 Cr | 1.66 Cr | 7.51 Cr | 2.01 Cr | 5.05 | 9.26 Cr | 0.0153 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.64 Cr | 487.41 Cr | 346.03 Cr | 141.3827 Cr | 167.15 Cr | 166.51 Cr | 239.89 Cr | 52.49 Cr | 0.00 Cr | 0.00 Cr | 4.55 Cr | 321.1771 Cr |
| 2024-03-31 | 1.07 Cr | 307.60 Cr | 186.13 Cr | 121.4712 Cr | 105.51 Cr | 104.44 Cr | 175.00 Cr | 46.15 Cr | 0.00 Cr | 0.00 Cr | 0.47 Cr | 166.8275 Cr |
| 2023-03-31 | 2.95 Cr | 257.28 Cr | 160.90 Cr | 96.3757 Cr | 86.55 Cr | 83.60 Cr | 150.12 Cr | 38.63 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 139.6567 Cr |
| 2022-03-31 | 1.94 Cr | 186.99 Cr | 118.93 Cr | 68.0606 Cr | 60.66 Cr | 58.72 Cr | 46.46 Cr | 32.28 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 73.7504 Cr |
| 2021-03-31 | 0.99 Cr | 161.62 Cr | 118.55 Cr | 43.0702 Cr | 39.64 Cr | 38.65 Cr | 67.57 Cr | 30.32 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 86.4558 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -29.0629 Cr | -6.3542 Cr | 39.1159 Cr | -35.1691 Cr | 3.6988 Cr | 5.2231 Cr | -6.1062 Cr | 20.0303 Cr | 61.6367 Cr | 0.0000 Cr | -64.8909 Cr |
| 2024-03-31 | -0.4387 Cr | -7.6391 Cr | 5.9930 Cr | -8.0778 Cr | -2.0849 Cr | 1.3502 Cr | -7.6391 Cr | 15.6234 Cr | 18.9634 Cr | 0.0000 Cr | -24.8743 Cr |
| 2023-03-31 | -14.4088 Cr | -9.4045 Cr | 25.1767 Cr | -23.9034 Cr | 1.3633 Cr | 3.4351 Cr | -9.4946 Cr | 10.8066 Cr | 6.8893 Cr | 0.0000 Cr | -103.6635 Cr |
| 2022-03-31 | -2.3802 Cr | -4.1430 Cr | 7.4668 Cr | -6.6662 Cr | 0.9436 Cr | 2.0718 Cr | -4.2860 Cr | 6.3353 Cr | 13.1251 Cr | 0.0000 Cr | 21.1144 Cr |
| 2021-03-31 | 0.1699 Cr | -1.3879 Cr | -0.7130 Cr | -1.2180 Cr | -1.9309 Cr | 1.1282 Cr | -1.3879 Cr | 2.0147 Cr | 4.7442 Cr | 0.0000 Cr | -17.1129 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 119.40 Cr | 88.06 Cr | 31.34 Cr | 0.2625 | 15.57 Cr | 6.77 Cr | 14.33 | 16.99 Cr | 0.0567 |
| 2025-03-31 | 165.44 Cr | 128.37 Cr | 37.07 Cr | 0.2241 | 12.96 Cr | 6.00 Cr | 12.71 | 17.25 Cr | 0.0363 |
| 2024-12-31 | 101.84 Cr | 77.65 Cr | 24.20 Cr | 0.2376 | 12.14 Cr | 5.33 Cr | 11.29 | 13.23 Cr | 0.0524 |
| 2024-09-30 | 106.89 Cr | 80.74 Cr | 26.15 Cr | 0.2446 | 12.43 Cr | 4.27 Cr | 9.05 | 13.95 Cr | 0.0400 |
| 2024-06-30 | 78.81 Cr | 64.98 Cr | 13.83 Cr | 0.1755 | 9.43 Cr | 4.13 Cr | 8.79 | 10.48 Cr | 0.0524 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.64 Cr | 6.54 Cr | 7.18 Cr | 177.59 Cr | 239.89 Cr | 427.95 Cr | 52.49 Cr | 487.41 Cr | 346.03 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 1.73 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -130.87 Cr |
| 2024-09-30 | 0.14 Cr | 10.27 Cr | 10.41 Cr | 116.14 Cr | 175.85 Cr | 302.64 Cr | 47.69 Cr | 355.42 Cr | 224.55 Cr |
| 2024-06-30 | -2.16 Cr | 4.32 Cr | 2.16 Cr | 0.00 Cr | 0.00 Cr | 2.16 Cr | 0.00 Cr | 0.00 Cr | -121.47 Cr |
| 2024-03-31 | 1.07 Cr | 1.05 Cr | 2.13 Cr | 64.85 Cr | 175.00 Cr | 257.20 Cr | 48.02 Cr | 307.60 Cr | 186.13 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 5.33 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 4.27 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 4.13 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 1.35 Cr | 1.35 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 5.06 Cr | -19.25 Cr | 0.52 Cr | 16.84 Cr | -1.89 Cr | 1.35 Cr | 3.24 Cr | 0.52 Cr | -18.73 Cr |
| 2023-12-31 | 4.64 Cr | -19.25 Cr | 0.52 Cr | 16.84 Cr | 1.97 Cr | 3.89 Cr | 1.92 Cr | 0.52 Cr | -18.73 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Medical - Pharmaceuticals
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| MedPlus Health Services Limited | MEDPLUS | ₹821.25 | ₹98,339,283,675.00 | ₹72,992.00 |
Key Executives
Gender: Not Specified
Year Born: 1945
Gender: male
Year Born: 1986
FAQs about Fredun Pharmaceuticals Limited
The CEO is Daulat N. Medhora.
The current price is ₹1,254.05.
The range is ₹635-1275.
The market capitalization is ₹592.12 crores.
The dividend yield is 0.06%.
The P/E ratio is 26.46.
The company operates in the Healthcare sector.
Overview of Fredun Pharmaceuticals Limited (ISIN: INE194R01017) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹592.12 crores and an average daily volume of 20,289 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.7.